From: Downregulation of B3GNT6 is a predictor of poor outcomes in patients with colorectal cancer
Variables | Testing cohort (n=443) | Validating cohort (n=123) | ||||
---|---|---|---|---|---|---|
High (n=170) | Low (n=273) | p value | High (n=49) | Low (n=74) | p value | |
Age | ||||||
≥65 | 101 | 166 | 0.7351 | 35 | 52 | 0.8901 |
<65 | 69 | 106 | 14 | 22 | ||
Unavailable | 0 | 1 | 0 | 0 | ||
Gender | ||||||
Male | 90 | 147 | 0.8527 | 32 | 41 | 0.2738 |
Female | 80 | 126 | 17 | 33 | ||
Stage | ||||||
I-II | 84 | 137 | 0.9321 | 28 | 48 | 0.3882 |
III-IV | 82 | 136 | 21 | 26 | ||
T stage | ||||||
T1-T2 | 21 | 26 | 0.3574 | 2 | 11 | 0.0625 |
T3-T4 | 145 | 239 | 43 | 59 | ||
Unavailable | 4 | 8 | 4 | 4 | ||
Lymph node metastasis | ||||||
Absent | 88 | 142 | 0.8803 | 26 | 46 | 0.3906 |
Present | 76 | 119 | 19 | 24 | ||
Unavailable | 6 | 12 | 4 | 4 | ||
Distant metastasis | ||||||
Absent | 150 | 226 | 0.1474 | 40 | 66 | 0.3078 |
Present | 16 | 38 | 4 | 3 | ||
Unavailable | 4 | 9 | 5 | 5 | ||
Tumor Location | ||||||
Distal | 96 | 171 | 0.1971 | 27 | 48 | 0.2772 |
Proximal | 74 | 102 | 22 | 26 | ||
MMR | ||||||
dMMR | 18 | 43 | 0.1222 | 5 | 9 | 0.6202 |
pMMR | 139 | 209 | 41 | 55 | ||
Unavailable | 13 | 21 | 3 | 10 | ||
CIMP status | ||||||
− | 111 | 195 | 0.1855 | 38 | 61 | 0.4994 |
+ | 33 | 41 | 8 | 9 | ||
Unavailable | 26 | 37 | 3 | 4 | ||
CIN status | ||||||
negative | 41 | 41 | 0.0205 | 17 | 11 | 0.0059 |
positive | 98 | 176 | 25 | 55 | ||
Unavailable | 31 | 56 | 7 | 8 | ||
tp53 mutation | ||||||
Mutated | 51 | 84 | 0.9483 | 20 | 35 | 0.2642 |
Wild type | 42 | 68 | 24 | 27 | ||
Unavailable | 77 | 121 | 5 | 12 | ||
Kras mutation | ||||||
Mutated | 84 | 88 | 0.0002 | 20 | 25 | 0.496 |
Wild type | 78 | 174 | 29 | 47 | ||
Unavailable | 8 | 11 | 0 | 2 | ||
Braf mutation | ||||||
Mutated | 19 | 25 | 0.4532 | 4 | 3 | 0.3401 |
Wild type | 130 | 218 | 44 | 69 | ||
Unavailable | 21 | 30 | 1 | 2 |